Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating the Tumor Microenvironment of KRAS-mutated Non-Small Cell Lung Carcinoma to Predict Anti-PD-1 Therapy Response

EF 2022-23

Résumé
The tumor microenvironment (TME) refers to the collection of molecules, both cellular and non-cellular, surrounding the tumor that regulate a person’s immune response. Immune cells are a key component of the TME; while some of these cells are beneficial to the tumor, others can suppress tumor growth. We can target these immune cells within the TME therapeutically for cancer treatment. For example, Anti-PD-1 therapy, a type of immunotherapy, targets the interaction between PD-1 and PD-L1, two proteins involved in the immune response. Anti-PD-1 therapy has become the therapy of choice in lung cancer treatment and across many other tumor types. The main drawback of this treatment, however, is that is only found to be effective in about 25% of patients. STK11/LKB1 (KL) genetic mutations are a main driver of resistance to anti-PD-1 therapy and associated with poor outcomes in lung cancer patients. Multiplex immunofluorescence (mIF) has become a popular technique to visualize the TME because of its ability to visualize multiple targets on a single tissue sample; in fact, it has been shown to be more effective than other widely used clinical tests in predicting patient response to anti-PD-1 therapy. In this study, we aim to characterize the TME of KL-mutated lung cancer patients using mIF to understand how it contributes to poor response to anti-PD-1 therapy. We will use a validated mIF panel protocol to stain lung cancer patient specimens and ultimately, compare immune cell expression patterns between patients with KL mutations to those without. This study will help to identify features within the TME that predict non-responders to anti-PD-1 therapy. More broadly, these findings will improve the overall treatment of lung cancer patients by using a patient-specific approach.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486050
Name
Vlaminck Darah J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Tumor Microenvironment of KRAS-mutated Non-Small Cell Lung Carcinoma to Predict Anti-PD-1 Therapy Response
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Pd-1 Therapy; Immunotherapy; Kras Mutation; Multiplex Immunofluorescence; Non-Small Cell Lung Carcinoma; Precision Treatment; Tumor Microenvironment
Abstract
The tumor microenvironment (TME) refers to the collection of molecules, both cellular and non-cellular, surrounding the tumor that regulate a person’s immune response. Immune cells are a key component of the TME; while some of these cells are beneficial to the tumor, others can suppress tumor growth. We can target these immune cells within the TME therapeutically for cancer treatment. For example, Anti-PD-1 therapy, a type of immunotherapy, targets the interaction between PD-1 and PD-L1, two proteins involved in the immune response. Anti-PD-1 therapy has become the therapy of choice in lung cancer treatment and across many other tumor types. The main drawback of this treatment, however, is that is only found to be effective in about 25% of patients. STK11/LKB1 (KL) genetic mutations are a main driver of resistance to anti-PD-1 therapy and associated with poor outcomes in lung cancer patients. Multiplex immunofluorescence (mIF) has become a popular technique to visualize the TME because of its ability to visualize multiple targets on a single tissue sample; in fact, it has been shown to be more effective than other widely used clinical tests in predicting patient response to anti-PD-1 therapy. In this study, we aim to characterize the TME of KL-mutated lung cancer patients using mIF to understand how it contributes to poor response to anti-PD-1 therapy. We will use a validated mIF panel protocol to stain lung cancer patient specimens and ultimately, compare immune cell expression patterns between patients with KL mutations to those without. This study will help to identify features within the TME that predict non-responders to anti-PD-1 therapy. More broadly, these findings will improve the overall treatment of lung cancer patients by using a patient-specific approach.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vlaminck, Darah J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~